BEAM
Price
$16.80
Change
-$0.34 (-1.98%)
Updated
Jun 27 closing price
Capitalization
1.69B
44 days until earnings call
VIVS
Price
$1.45
Change
+$0.03 (+2.11%)
Updated
Jun 27 closing price
Capitalization
3.82M
Interact to see
Advertisement

BEAM vs VIVS

Header iconBEAM vs VIVS Comparison
Open Charts BEAM vs VIVSBanner chart's image
Beam Therapeutics
Price$16.80
Change-$0.34 (-1.98%)
Volume$4.49M
Capitalization1.69B
VivoSim Lab
Price$1.45
Change+$0.03 (+2.11%)
Volume$21.82K
Capitalization3.82M
BEAM vs VIVS Comparison Chart in %
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. VIVS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and VIVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (BEAM: $16.80 vs. VIVS: $1.45)
Brand notoriety: BEAM and VIVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 238% vs. VIVS: 11%
Market capitalization -- BEAM: $1.69B vs. VIVS: $3.82M
BEAM [@Biotechnology] is valued at $1.69B. VIVS’s [@Biotechnology] market capitalization is $3.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileVIVS’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • VIVS’s FA Score: 1 green, 4 red.
According to our system of comparison, VIVS is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while VIVS’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 5 bearish.
  • VIVS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both BEAM and VIVS are a bad buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а +0.18% price change this week, while VIVS (@Biotechnology) price change was -0.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.69B) has a higher market cap than VIVS($3.82M). VIVS YTD gains are higher at: 215.286 vs. BEAM (-32.258). VIVS has higher annual earnings (EBITDA): -2.21M vs. BEAM (-399.03M). BEAM has more cash in the bank: 1.22B vs. VIVS (11.3M). VIVS has less debt than BEAM: VIVS (942K) vs BEAM (158M). BEAM has higher revenues than VIVS: BEAM (63.6M) vs VIVS (144K).
BEAMVIVSBEAM / VIVS
Capitalization1.69B3.82M44,165%
EBITDA-399.03M-2.21M18,056%
Gain YTD-32.258215.286-15%
P/E RatioN/AN/A-
Revenue63.6M144K44,167%
Total Cash1.22B11.3M10,796%
Total Debt158M942K16,773%
FUNDAMENTALS RATINGS
VIVS: Fundamental Ratings
VIVS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
PROFIT vs RISK RATING
1..100
95
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMVIVS
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
89%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 14 days ago
85%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XRTX0.950.11
+13.10%
XORTX Therapeutics
WGO29.261.02
+3.61%
Winnebago Industries
VALN5.800.05
+0.87%
Valneva SE
KNSL473.31-3.09
-0.65%
Kinsale Capital Group
ZNTL1.18-0.08
-6.35%
Zentalis Pharmaceuticals

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-1.98%
CRSP - BEAM
72%
Closely correlated
N/A
RXRX - BEAM
64%
Loosely correlated
-6.85%
NTLA - BEAM
63%
Loosely correlated
-0.52%
DNLI - BEAM
61%
Loosely correlated
-2.69%
SYRE - BEAM
59%
Loosely correlated
-4.99%
More

VIVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with GLTO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then GLTO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIVS
1D Price
Change %
VIVS100%
+2.11%
GLTO - VIVS
38%
Loosely correlated
-2.29%
KRRO - VIVS
26%
Poorly correlated
-3.16%
ADIL - VIVS
25%
Poorly correlated
-28.67%
BEAM - VIVS
25%
Poorly correlated
-1.98%
LSB - VIVS
25%
Poorly correlated
-2.76%
More